EUVIMEDEUVIMED entdecken
Crossref

Evaluating birth outcomes following oral rilpivirine use in pregnancy in the United States : Findings from the antiretroviral pregnancy registry

William R Short, Corinne Willame iD, Henry Nguyen, Bohui Zhang, Ping Xu iD, Eileen Birmingham, Rodica Van Solingen-Ristea, Bryan Baugh

HIV Medicine · 2026

DOI: 10.1111/hiv.70112 ↗

Kurz gefasst

Fachartikel in der Zeitschrift HIV Medicine, 2026. Verfasst von William R Short und 7 weiteren Autor:innen. Beteiligte Einrichtung: Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Rilpivirine, Pregnancy Outcome, Pregnancy Complications, Infectious, HIV Infections. Die Arbeit nennt 16 Literaturangaben. Gefördert von: Johnson and Johnson.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The Antiretroviral Pregnancy Registry (APR) is designed to detect major teratogenic effects of antiretroviral medications; other pregnancy outcomes are also recorded when reported. We compared available pregnancy and birth outcomes of women exposed to oral rilpivirine‐containing regimens (oral‐RPV cohort) versus non‐rilpivirine regimens (non‐RPV cohort) over the period 2011 to 2023.

Methods

Maternal age‐adjusted prevalence ratio (aPR) of pregnancy and birth outcomes was compared for prospectively reported pregnancies; aPR of birth defects was compared between first‐trimester exposures and combined second/third‐trimester exposures.

Results

In total, 6937 pregnancies were recorded, including 4617 (oral‐RPV cohort, 781 [16.9%]; non‐RPV cohort, 3836 [83.1%]) from the United States. Among live births, the prevalence of birth defects was lower in the oral‐RPV cohort (1.6% versus 3.8%; aPR: 0.4 [95% confidence interval (CI): 0.2–0.8]). The prevalence of birth defects in the first‐trimester oral‐RPV exposure versus second/third‐trimester exposure did not differ (aPR: 3.4 [95% CI: 0.4–26.3]). The aPR of induced abortions (1.1 [0.6–1.9]), stillbirths (0.6 [0.2–1.6]) and premature birth (0.8 [0.7–1.1]) were similar between cohorts. Prevalences for spontaneous abortion were 5.8% (oral‐RPV cohort) versus 3.2% (non‐RPV cohort) below the expected background rate (15%–20%). Low birth weights were less reported in oral‐RPV, while very low birth weights were similar between cohorts.

Conclusions

Review of available data from the APR does not indicate an association between adverse pregnancy or birth outcomes and oral‐RPV exposure, overall or by timing of exposure. Since APR targets primarily teratogenic effects, findings for non‐teratogenic effects should be interpreted with caution.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RilpivirinePregnancy OutcomePregnancy Complications, InfectiousHIV InfectionsAnti-HIV AgentsAbnormalities, Drug-InducedHumansFemalePregnancyUnited StatesAdultRegistriesAdministration, OralInfant, NewbornPrevalenceYoung Adult

Stichwörter der Autor:innen

antiretroviral therapybirth defectshuman immunodeficiency virus‐1pregnancy outcomesrilpivirine

Substanzen

RilpivirineAnti-HIV Agents

Autor:innen und Institutionen

  • Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Johnson & Johnson, Beerse, Belgium.
  • Johnson & Johnson, Titusville, New Jersey, USA.
  • Syneos Health, Morrisville, North Carolina, USA.
  • Johnson & Johnson, Raritan, New Jersey, USA.

ORCID-Profile: Corinne Willame, Ping Xu

Förderung

  • Johnson and Johnson

Zitieren

APA

Short, W. R., Willame, C., Nguyen, H., Zhang, B., Xu, P., Birmingham, E., Van Solingen-Ristea, R., & Baugh, B. (2026). Evaluating birth outcomes following oral rilpivirine use in pregnancy in the United States : Findings from the antiretroviral pregnancy registry. HIV Medicine. https://doi.org/10.1111/hiv.70112

Vancouver

Short WR, Willame C, Nguyen H, Zhang B, Xu P, Birmingham E, et al. Evaluating birth outcomes following oral rilpivirine use in pregnancy in the United States : Findings from the antiretroviral pregnancy registry. HIV Medicine. 2026. doi:10.1111/hiv.70112

BibTeX
@article{Short2026,
  author = {Short, William R and Willame, Corinne and Nguyen, Henry and Zhang, Bohui and Xu, Ping and Birmingham, Eileen and Van Solingen-Ristea, Rodica and Baugh, Bryan},
  title = {Evaluating birth outcomes following oral rilpivirine use in pregnancy in the United States : Findings from the antiretroviral pregnancy registry},
  journal = {HIV Medicine},
  year = {2026},
  doi = {10.1111/hiv.70112}
}
Kostenlos starten →